What this covers

This EconTalk conversation pairs Russ Roberts with Richard Epstein, who is discussing his book Overdose. It starts from first principles of property: why information differs from land, why public ownership allows access but blocks intensive investment, and why every legal system limits a patent to a fixed term before the invention enters the public domain. Epstein then applies that framework to pharmaceuticals, where the first pill costs about a billion dollars and the second about three, so later buyers have to pay above marginal cost. He also argues that a patent is a right to exclude, not a monopoly, because rivals can build close substitutes with slightly different mechanisms.

The range is wide. On patents, he separates incentive from funding (expected rewards motivate spending today), treats the injunction as essential for pharmaceuticals but a nuisance in software, where unknowing infringement is nearly certain, and predicts that price caps will push firms away from exotic diseases. On the FDA, he frames regulatory mistakes as Type I and Type II errors, arguing that unseen deaths from withheld drugs outweigh the visible harms of approval. He puts a value of several hundred thousand dollars on a year of healthy life, and he suggests private certifiers like Underwriters Laboratories could replace the agency.

The more contested turns concern industry politics and generics. Roberts raises Bruce Yandle's Bootleggers and Baptists to explain why large firms tolerate regulation whose fixed costs shut out startups, though Epstein counters that in-licensing sends most of the creative premium to small biotech innovators. He also argues that generics are not truly identical, that they face a Lemons Problem, and that third-party payment dilutes their price advantage. He closes on off-label use, which is a majority of cancer-drug use, on informed chronic-disease patients, and on dosing errors among elderly people on complex regimens.

Sharpest takeaway

Epstein argues that strong, time-limited patent and property rights are what drive pharmaceutical innovation, and that FDA delay, over-warning, and one-size-fits-all regulation cost more lives than the drug harms they prevent, partly because regulation protects large incumbents.

  • Patents must be strong enough to prevent poaching because pharma R&D costs about a billion dollars per drug and a blockbuster can earn $13-14 billion a year
  • FDA approval delays shorten effective patent life to about 8-9 years and cost patients more in lost treatment time than rare drug deaths
  • Large incumbents benefit from regulatory compliance costs that startups cannot bear, so they tolerate or support regulation (bootleggers and Baptists)

The claims · ranked72 claims · weighted by value

This asset isn't compiled yet

You're seeing its claims, ranked. Compile it to build the argument threads, weight them, and check each claim against your library — the full view.

0.86

Information differs from land because it can be used and disseminated at the same time (land can be planted or eaten, not both), which is why every legal system limits copyrights and patents to a finite duration before the invention enters the public domain.

causalhigh valueestablishednovelty 3/4durability 4/4· Richard Epstein

“with land, you could plant your seed or you could eat your seed. You can't do both. With information, there's a way to both use it and to disseminate it.”

0.86

Drugs cannot be priced at marginal cost because the first pill costs about a billion dollars while the second costs about three dollars, and no buyer pays for the first; so the patent holder must charge later buyers above marginal cost to recoup fixed costs.

causalhigh valueestablishednovelty 3/4durability 4/4· Richard Epstein

“It cost you a billion dollars to make the first pill, it cost you three dollars to make the second one”

0.81

Patents do not exempt a drug from FDA approval, and because generic competitors would benefit from the approved product without paying for trials, no one funds a generic through FDA review; innovators must secure the patent first and then endure approval that can take 8-10 years from invention to license.

causalhigh valueestablishednovelty 3/4durability 3/4· Richard Epstein

“Nobody will spend a fortune taking a generic product through the FDA knowing that once it's approved, other people will be able to piggyback”

0.80

Public property permits access but prevents intensive use, while private property enables intensive investment because owners can expect to recover today's investment tomorrow, and that investment profits others through leases, licenses, and trade.

causalhigh valueestablishednovelty 2/4durability 4/4· Richard Epstein

“you can now really make very intensive investments, knowing that anything that you put in today, you'll be able to take back tomorrow”

0.80

Generic drugs suffer from a lemons problem: if buyers cannot tell good generics from bad, generic brands cannot justify spending on quality, which weakens the generic market, though HMOs may help by screening suppliers.

causalhigh valueestablishednovelty 2/4durability 4/4· Richard Epstein

“then there's the lemons problem. If you know that there's an issue out there, you're not quite sure which of these generics are good”

0.80

Regulatory error has two types: Type I errors (approving a drug that should not be used, which is highly visible) and Type II errors (withholding a drug that should be used, which is invisible); banning all drugs would eliminate Type I errors but cause deaths from untreated conditions, so the goal is minimizing the sum of both.

causalhigh valueestablishednovelty 2/4durability 4/4· Richard Epstein

“there are two kinds of error. One of them is using something which ought not to be used, call that type one error, and the other one is not using something that ought to be used, which is type two error”

0.78

Drug companies benefit from FDA regulation because compliance costs are a fixed cost startups cannot bear, excluding rivals; in Bruce Yandle's bootleggers-and-Baptists terms, companies are the bootleggers and safety advocates are the Baptists, producing a strong political coalition for an overly zealous FDA.

causalhigh valuecontestednovelty 3/4durability 4/4· Russ Roberts

“it creates this enormous fixed cost of compliance. It can't be done by a startup... they're the bootleggers. The Baptists are the folks who say, 'Ooh, it's dangerous'”

0.78

Fragmented land ownership over generations creates unusable plots and disputes, so primogeniture was adopted to keep parcels whole; likewise, many small rights that must combine are hard to assemble, yet cartel-like price fixing among competing viable firms must be avoided.

causalhigh valuecontestednovelty 3/4durability 4/4· Richard Epstein

“small broken things don't work well if all of them have to combine”

0.78

Anecdotes of drug deaths from the bottom tail of the outcome distribution mislead; regulators should look at the top tail of beneficial outcomes too, since the law of averages guarantees some bad outcomes in any large population.

normativehigh valuecontestednovelty 3/4durability 4/4· Richard Epstein

“If all you do is you look at the bottom tail, you can guarantee that the law of averages will make that big. But you can shift the distribution”

0.75

Pharmaceutical patents are unusually valuable: a new molecular entity can cost about a billion dollars to develop and test, yet a blockbuster like Lipitor can sell $13-14 billion in a year, mostly profit, so without strong injunctive protection a competitor can turn $14 billion into $14 million quickly.

causalhigh valueestablishednovelty 2/4durability 3/4· Richard Epstein

“you can take $14 billion and turn it into $14 million more quickly than you can say Jack Sprat”

0.74

Patents do not fund R&D through their profits; instead, the expectation of future patent rewards creates the incentive to spend R&D money today, and public policy does not use patents as a revenue guarantee.

causalhigh valuecontestednovelty 3/4durability 4/4· Richard Epstein

“The economics, the intuition is that the rewards of the patent down the road create the incentive to spend the R&D money today.”

0.74

A patent is more accurately the right to exclude others from a patented invention, not a monopoly, because drugs face close substitutes: a rival can develop a molecule with a slightly different mechanism, much like two beer companies with different flavors competing.

definitionhigh valuecontestednovelty 3/4durability 4/4· Richard Epstein

“a more technically accurate word is the right to exclude others from the use of your patented invention”

0.73

Capping drug prices will not merely lower profits while preserving innovation; firms will abandon exotic diseases and unpromising paths, so the surviving projects earn higher returns and political pressure then restarts the cycle.

forecasthigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“what they will do is they will stop going after exotic diseases, they will stop going into new paths”

0.73

The largest drug-related deaths come from elderly patients managing complex regimens of many drugs on different schedules, so one-a-day pills reduce dosing errors dramatically and reforms should focus on systematic observation of the final delivery step.

normativehigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“One of the real advances... is getting a one-a-day pill... the error that you have associated with its application goes down hugely”

0.73

Generic drugs are not identical to branded versions: fillers, delivery systems, and shelf-life reliability can differ, and producers' incentives to be careful vary, so generics can be an inferior product at a lower price, which reduces willingness to switch.

factualhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“They're not identical. They may be close but they're not identical.”

0.73

Patent infringement does not require proof of intentional copying, so large software products with millions of lines of code almost certainly infringe some patent unknowingly, making injunctions a nuisance and a royalty the more efficient remedy.

causalhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“you don't have to prove that there was conscious duplication of copy. That's the copyright rule. It's not the patent rule.”

0.73

Without the FDA, drug companies would create their own certification laboratories (like Underwriters Laboratories) because brand reputation makes quality assurance valuable, so the FDA's claim to be the only purity guarantor is overdrawn.

forecasthigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“they would create their own underwriting laboratories for the FDA. And they'd have a brand name to protect.”

0.73

The standard argument that people are ignorant and would take unnecessary risk misses that patients with chronic conditions become highly informed and active, so the passive-patient model is wrong for chronic disease and incentives should encourage that engagement.

causalhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“in chronic cases, it's a mistake to assume the ignorant passive model. People who have a lot on the line all of a sudden become intelligent and active”

0.73

A large drug company with an approved drug facing a competitor can delay the rival's FDA entry by a year or two and thereby extend its market monopoly beyond its patent monopoly, which is why regulatory delay can be strategically valuable.

causalhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“if you could delay its entrance by a year or two, it will not only give you a patent monopoly, but it will give you a market monopoly through FDA regulation”

0.73

In-licensing lets small biotech innovators team up with large pharma, and because competition for licenses is steep, most of the creative premium goes to the small innovator, so incumbents cannot use regulation to keep small rivals out.

causalhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“most of the creative premium goes to the little guy, not to the big guy”

0.73

Physicians dislike the FDA because it cannot regulate medical practice but can restrict research and off-label discussion; much drug use is unauthorized, and cancer drugs are used off-label for majority of their usage, so an informal gray market has grown up.

factualhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“I've been told that the many cancer drugs the majority of its usage is in fact for unauthorized uses”

0.73

Generic drug prices may not fall much for consumers when most payments are made by third parties, so the price advantage of generics is diluted when insurers, not patients, bear the cost.

causalhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“if most of the payments are being made third party that price drop isn't as effective”

0.73

A year of healthy life is worth several hundred thousand dollars in subjective value, so delaying a drug by two years can harm a million people, and this welfare loss dominates the losses from the few people who would be harmed by approving the drug earlier.

factualhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“if you can give a person an additional healthy year of life for most people it's worth several hundred thousand dollars in subjective value”

0.73

Growth of third-party payment in the US over roughly 50 years means fewer people spend their own money on drugs, which raises drug profitability beyond what it would be if price-sensitive consumers were choosing, even though government price bargaining should still be resisted.

causalhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“the amount of third-party payment in the United States has gone up dramatically... fewer and fewer people are making their decisions with their own money”

0.72

Societies settle on a stable equilibrium of both common property (open access governed by rules, like roads and beaches) and private property (exclusive ownership), because geometry and access problems mean neither alone works: long linear assets like roads need assembly and eminent domain, while factories and farms need exclusive, intensive use.

causalhigh valuecontestednovelty 2/4durability 4/4· Richard Epstein

“we have a kind of a stable equilibrium between common property... and private property, which is subject to exclusive ownership”

0.72

Prizes, professorships, and Nobel Prizes cannot replace patent incentives because most would-be inventors, such as the 9,000 kids starting in garages of whom 8,900 are likely to fail, cannot be individually rewarded; exclusive rights must create the same investment dynamic for ideas that property creates for land.

causalhigh valuecontestednovelty 2/4durability 4/4· Richard Epstein

“you can't give a professorship to, you know, 9,000 kids who are starting out in garages, 8,900 of whom are likely to fail”

0.71

The Hatch-Waxman Act of 1984 restores patent term for FDA review time, roughly one day for every two days spent in regulatory process up to a cap, but the restoration becomes less effective the longer review drags on, so effective market life has shrunk to about 8-9 years for many drugs.

factualhigh valueestablishednovelty 2/4durability 3/4· Richard Epstein

“the Hatch-Waxman Act, colloquially, which essentially gives you patent extensions... for every 2 days that you are basically tied up in the FDA, you'll get 1 day at the end of the term”

0.70

Large drug companies have weakened incentives to block entrants because they hold portfolios of drugs in development and approved drugs that are wasting assets, so they cannot know whether they are defending a monopoly or trying to enter one.

causalhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“you don't know whether you're the guy who's in and trying to preserve a monopoly, or whether you're the guy who's out trying to come in and break it”

0.70

Pharmaceutical patents differ from software patents: pharma involves a few enormous single-molecule patents, so injunctions that operate like keeping trespassers off a skyscraper site are appropriate, while the assembly problem of many small overlapping patents calls for different rules.

normativehigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“with respect to pharmaceuticals at least, you're not talking about lots of small patents that work in combination”

0.69

The patent system is centralized in registration (a patent office gives notice to the world and examines validity) but decentralized in decisions: which patents are filed and which investments are made is determined privately by entrepreneurs, not by government industrial policy.

causalhigh valuecontestednovelty 2/4durability 4/4· Richard Epstein

“the genius is the question of what patents are filed by what individuals after what kind of investment decisions are always made privately”

0.69

Most opponents of the pharmaceutical industry's structure want the FDA, NIH, or government to run industrial policy by choosing which drug pathways to pursue, and that approach always loses to decentralized information because bureaucracy is sluggish.

normativehigh valuecontestednovelty 2/4durability 4/4· Richard Epstein

“Decentralized information will trump centralized control with all of its bureaucratic sluggishness every time”

0.68

FDA warnings are often too stringent, scaring off patients for whom a drug is beneficial, and people therefore rely on doctors or independent websites to make their own risk-benefit trade-offs.

causalhigh valuecontestednovelty 2/4durability 3/4· Richard Epstein

“the FDA warnings are too stringent in some cases and there are certain risk-benefit trade-offs that people would be better making with independent information”

0.68

Drug development carries a heavy cost of capital and high failure risk: Pfizer abandoned a cholesterol pill after clinical trials went badly despite sinking a billion dollars or more, so the interest rates and returns required to fund drugs must reflect this volatility.

causalhigh valueestablishednovelty 2/4durability 3/4· Richard Epstein

“The Pfizer company tried to put forward a new cholesterol pill, and they pulled the plug on the stuff after all the clinical trials turned out bad”

0.68

Longer supply chains weaken quality control: importing drugs from low-volume export markets gives exporting countries little incentive to inspect them, and cases like diluted anesthetics in Brazil show real harm, so re-importation carries counterfeit risk.

causalhigh valuecontestednovelty 2/4durability 3/4· Richard Epstein

“the longer the supply chain, the greater the chinks in the armor... the locals just don't want to run inspections for drugs that are not going to be used by local people”

0.66

Drug companies pay PDUFA user fees (the 1993 Prescription Drug User Fee Act, renewed repeatedly) to speed FDA review, which shows they do not primarily seek to slow the FDA for anti-competitive reasons.

factualhigh valuecontestednovelty 3/4durability 3/4· Richard Epstein

“if they were really interested in slowing down the FDA, they would not be paying money to speed it up”

0.65

Generic drugs lose sales in absolute units after going generic partly because without a brand name and advertising, the drug disappears from prescribers' attention, which led Chicago colleagues Tom Philipson and Darius Lakdawalla to argue that longer patent terms could help consumers.

causalhigh valuecontestednovelty 3/4durability 2/4· Richard Epstein

“often times the sale of drugs goes down in absolute units when they become generic”

0.64

Liability law turns FDA labeling into a minimum rather than an optimum, so lawyers can argue after the fact for stronger warnings, producing over-warning in which warnings are too stringent and patients rightly ignore them.

causalhigh valuecontestednovelty 2/4durability 3/4· Richard Epstein

“anything the FDA says about a warning is always a minimum and never an optimum”

0.63

The diabetes drug Rezulin helped some patients a great deal and killed others; after the FDA banned it, patients hoarded their supply because it had transformed their lives, showing that bans remove beneficial options for high-variance drugs that could instead be managed with monitoring.

causalhigh valuecontestednovelty 2/4durability 2/4· Richard Epstein

“These people won't give you their drugs back... They can get out of bed in the morning because they took this.”

0.63

The drug pipeline is thin: Pfizer's layoff of about 7,000 employees in recent months is emblematic of uncertainty about whether the industry can repeat past innovation, partly because scientific advance is harder and partly because of a hostile regulatory environment and barriers to entry.

forecasthigh valuecontestednovelty 2/4durability 2/4· Richard Epstein

“the Pfizer situation where they laid off 7,000 people or so in the last couple of months”

0.63

The effective market life of pharmaceutical patents has shrunk to about 8-9 years for many drugs, while development and capital costs have risen, creating a squeeze that reduces innovation returns.

factualhigh valuecontestednovelty 2/4durability 2/4· Richard Epstein

“They're now around 8 or 9 years for many drugs. And at the same time, you've got higher and higher costs”

0.62

Economist William Nordhaus's estimates suggest an innovator under strong property rights keeps only about 10-25% of the social surplus from a new billion-dollar patent, and Epstein argues this is still a very good deal for society.

factualhigh valuecontestednovelty 3/4durability 2/4· Richard Epstein

“if somebody creates say a billion dollars in social surplus from a new patent, probably the entrepreneur... gets to keep maybe between 10 and 25%”

0.61

Because manufacturers cannot warn about side effects of unauthorized uses without implicitly acknowledging approval, information about off-label risk is generated privately, creating a stable shadow economy whose existence shows the above-board regulated system is inefficient.

causalhigh valuespeaker onlynovelty 4/4durability 3/4· Richard Epstein

“that's basically a perfectly stable equilibrium... So there is this kind of shadow economy out there which is a sign that the above board economy is not efficient”

0.60

When bootlegger-Baptist coalitions do operate, the bootleggers often do not recognize their own interest and convince themselves they are the altruists, while their incentives push them toward that public-spirited language.

causalhigh valuespeaker onlynovelty 3/4durability 4/4· Richard Epstein

“a lot of times the bootleggers don't even they're not even aware of it. They actually can convince themselves they're on the side of the good guys”

0.57

Patients with serious conditions should be allowed a stratified strategy for risky drugs: start with a potent drug, and if intolerant step down to a less potent version, while those who tolerate it gain large benefits, so banning a drug forecloses this individualized path.

normativehigh valuespeaker onlynovelty 3/4durability 3/4· Richard Epstein

“you want to start with a strong drug and see if it's going to make you sick to your stomach... ratchet down to something which is a little less potent”

0.57

Trial lawyers are the main backers of tougher FDA standards, because a perceived slow FDA makes tort suits as backup remedies more credible and valuable, so they want the FDA under siege but not so strict that drugs never reach market and create nothing to sue over.

causalhigh valuespeaker onlynovelty 3/4durability 3/4· Richard Epstein

“the folks who are constantly pushing higher quality controls for the FDA... will be trial lawyers”

0.54

FDA stringency sits at an equilibrium between the two coalitions: if Baptists want inspection at 50 and bootleggers want 30, a current level of 40 means Baptists push for more and bootleggers push for less, and the current setting is roughly where the forces balance.

causalhigh valuespeaker onlynovelty 3/4durability 3/4· Russ Roberts

“Let's suppose that the Baptists would like to have the level of inspection is 50. And the bootleggers... want it down at 30”

0.51

The FDA works at roughly 70% social efficiency on contamination and corruption issues but only about 5% efficiency on banning drugs, so its largest problem is drug bans and its attention should focus there.

factualhigh valuespeaker onlynovelty 3/4durability 2/4· Richard Epstein

“the FDA's is basically working at 70% of social efficiency on the contamination and corruption issues, and it's working at 5% efficiency when it starts coming to banning drugs”

0.49

Despite the bootlegger theory, the dominant force behind strict FDA oversight is the more traditional Baptist motive of safety purists, not incumbents' desire to exclude rivals, and Epstein has never heard a pharma company's real motive described as anti-competitive.

normativehigh valuespeaker onlynovelty 2/4durability 2/4· Richard Epstein

“More the purists who are keeping this out. I have worked extensively with Pharma as a consultant”

0.48

Intellectual property follows the same logic as physical property: there must be a public domain of common language and knowledge (you cannot copyright 'good morning' or the Pythagorean theorem) alongside private rights that give inventors reason to make large investments.

normativeestablishednovelty 1/4durability 4/4· Richard Epstein

“you can't patent the words good morning... or copyright the Pythagorean theorem, because everybody else is going to do mathematics”

0.45

Government Medicaid purchasing and HMO formularies with bulk purchasing can lower prices by guaranteeing volume, and HMOs play rival drugs in a class against each other, which creates price variation where no two people pay the same price.

factualestablishednovelty 2/4durability 3/4· Richard Epstein

“no two people pay the same price because the way in which all these forces work”

0.41

Pricing common-access facilities such as roads by usage can vastly increase their carrying capacity, so common-access resources do not require abandoning markets.

causalcontestednovelty 2/4durability 3/4· Richard Epstein

“if we price the way in which people use the common access facilities, we can vastly increase its carrier capacity”

0.40

Consumer surplus is the reason society benefits from patents: a patient who pays $10 for a life-saving pill may value it at $100, capturing a $90 surplus that the innovator cannot fully capture.

causalestablishednovelty 1/4durability 4/4· Richard Epstein

“if I pay $10 for a pill which is going to save my life, I may benefit $100”

0.39

Counterfeiting and trademark deception require coercive enforcement such as seizure, destruction, and arrest, which turns it into a criminal matter, so companies cannot protect their brands through quality alone and government involvement becomes necessary.

causalestablishednovelty 1/4durability 3/4· Richard Epstein

“They have to prevent them protect themselves against a set of rogues who will destroy the confidence in their brand”

0.39

Standard view: FDA bureaucrats are overly cautious because visible Type I errors (approved drugs that harm) draw political blame while invisible Type II errors (unapproved drugs that would have helped) do not, creating a natural bias toward caution.

causalestablishednovelty 1/4durability 3/4· Russ Roberts

“the harm is visible, and they'll pay a political price for it, whereas the other type of error of not allowing a drug, well, that drug's never seen”

0.38

Drug advertising must list all side effects, which yields absurd broadcast ads where the warnings are discounted, because a long recitation of risks is the only way to avoid liability for touting benefits.

causalestablishednovelty 1/4durability 2/4· Russ Roberts

“you've got to expose people to the bad stuff... So, what you do is you get the speed readers out there, and therefore everybody just completely discounts it”

0.35

Pharmaceutical companies want injunctions against patent infringers and oppose compulsory licenses, because with a few high-value patents unshielded infringers would poach and the system would collapse, whereas software companies are more ambivalent and prefer royalties.

factualestablishednovelty 1/4durability 3/4· Richard Epstein

“they hate compulsory licenses and they love injunctions. The software people are much more ambivalent.”

0.35

Drug prices differ across nations because state monopolies in Canada and Europe offer low prices or threaten generic licensing, so manufacturers are forced into differential pricing, which fuels re-importation pressure.

causalestablishednovelty 1/4durability 3/4· Richard Epstein

“you often face state monopolies... you want to sell in Canada, what you have to do is give it a very attractive price”

0.34

The FDA's uniform risk-return approach reflects bureaucratic arrogance that all patients are alike, and compassionate-use exemptions favor those with political connections while others are told to wait, so the regulatory system is effectively one-size-fits-all.

normativespeaker onlynovelty 2/4durability 3/4· Richard Epstein

“it's a kind of at this point bureaucratic arrogance that all people are alike”

0.34

Drug interactions are a major hazard: mixing a potent drug with alcohol can be fatal, which led one drug to be removed; grapefruit juice interferes with absorption of many drugs, and patients on many medications should avoid it.

factualestablishednovelty 0/4durability 4/4· Richard Epstein

“if somebody took this drug with six shot glasses of alcohol, uh they could die. So you take it off the market.”

0.32

New entry into pharmaceuticals remains possible without prior profits because entrepreneurs can raise venture capital, so the system is not closed to newcomers who have no earlier drug revenue.

factualcontestednovelty 1/4durability 3/4· Richard Epstein

“if somebody doesn't have a dime of profits from previous pharmaceutical inventions, they can still scrape together venture capital”

0.30

Medicaid's near-100% subsidy for drug purchases has been offset by government demands for lower prices in exchange for guaranteed market access, showing that excess demand from subsidies can be addressed through bargaining.

factualestablishednovelty 1/4durability 2/4· Richard Epstein

“you have a huge, almost 100% subsidy for purchase. And what the government has just come in and has demanded and has received, um, lower prices”

0.30

Many drugs in the US are priced inconsistently, and the US pharmaceutical market is relatively unregulated on price, which produces complicated bargaining games that cannot be reliably fixed by price controls.

factualestablishednovelty 1/4durability 2/4· Richard Epstein

“when we sell drugs in the United States, it's relatively unregulated market on the price dimension. So you get all of these bargaining games”

0.30

A drug interaction caused an alcohol-related death risk in a withdrawn product: a drug combined with heavy alcohol was dangerous enough to be pulled, though no one has been documented mixing potent drugs with alcohol in such a way.

factualestablishednovelty 1/4durability 2/4· Richard Epstein

“if somebody took this drug with six shot glasses of alcohol, uh they could die”

0.30

Counterfeiting in Brazil has included diluting drugs, which can cause anesthesia to wear off early and patients to wake during surgery, illustrating why supply-chain integrity matters.

factualestablishednovelty 1/4durability 2/4· Richard Epstein

“one of the forms of counterfeiting of their drugs that took place in Brazil was to thin them, dilute them”

0.29

The Veterans Administration's policy of excluding new drugs from its formulary for two to three years pushed patients to demand freedom to choose other plans, showing that patients can exit a VA plan but cannot exit the FDA's licensing requirement.

factualspeaker onlynovelty 2/4durability 3/4· Richard Epstein

“you can run from it and go to some other kind of plan. You can't run from the FDA”

0.29

Redistribution aimed at innovation is unsustainable because people get wealthy only when others get wealthy; strategies that beggar others, including innovation-limiting redistribution, can shut down entire social systems.

normativespeaker onlynovelty 0/4durability 4/4· Richard Epstein

“the only way people get wealthy in a capitalist or indeed any society is if other people get wealthy”

0.28

The FDA has refused to certify overseas drugs against counterfeiting and every FDA commissioner regardless of party has declined to give this seal, but Epstein argues that some counterfeit fears are scare tactics used to protect monopoly.

factualspeaker onlynovelty 2/4durability 2/4· Richard Epstein

“every FDA commissioner regardless of party or affiliation has refused to as it were give a seal of approval against these kinds of issues coming from overseas”

0.24

The US utility patent term of about 20 years, which covers most pharmaceuticals, is the current balance between protecting invention and returning it to the public domain.

factualestablishednovelty 0/4durability 2/4· Richard Epstein

“you get basically 20 years for what they call the utility patent, which would cover most pharmaceuticals”

0.21

Under the current policy framework, the FDA's approach to patents and drug risk is appropriate because there is no way to avoid the trade-off; but the agency could usefully focus on purity testing rather than broad bans.

normativespeaker onlynovelty 1/4durability 2/4· Richard Epstein

“the one thing that it might do sensibly is on the purification side”

0.18

Generic drugs have high unit volume but less than about 20% of total pharmaceutical sales in dollar terms, showing the market is complicated and that heavy-handed price regulation risks disrupting mechanisms regulators do not fully understand.

factualspeaker onlynovelty 1/4durability 1/4· Richard Epstein

“it's probably less than 20% I think of the total market”

0.17

The patent system has worked remarkably well despite handicaps like shortened effective life, high trial costs, and capital costs, but it has come under attack.

normativespeaker onlynovelty 0/4durability 2/4· Richard Epstein

“It has worked amazingly well, um even with all these handicaps, but it has come under attack today.”

0.10

Brief sign-off: the host thanks the guest and the episode closes with production credits.

factualspeaker onlynovelty 0/4durability 0/4· Russ Roberts

“Richard, thanks for joining us.”